



## Altimune to Announce Third Quarter 2021 Financial Results on November 10, 2021

November 3, 2021

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

Altimune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.

### Conference Call Information:

Date: Wednesday, November 10  
Time: 8:30 am Eastern Time  
Domestic Dial-in: (844) 615-6509  
International Dial-in: (918) 922-3148  
Conference ID: 5783655  
Webcast: <https://edge.media-server.com/mmc/p/zgrrmubx>

### About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimune, please visit [www.altimmune.com](http://www.altimmune.com).

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

### Investor and Media Contact:

Will Brown  
Chief Financial Officer  
Phone: 240-654-1450  
[wbrown@altimmune.com](mailto:wbrown@altimmune.com)



Source: Altimune, Inc